A partnership that benefits patients
What is a clinical trial and how to participate.
Look at our future science
Review our clinical pipeline
What is a clinical trial and how to participate
We have teamed up with the International Red Cross and Red Crescent Movement to solve the challenge of delivering care to vulnerable populations displaced by conflict.
Click through to find the answers to some of our more frequently asked questions on sustainability and responsible business practices.
We are driven by science, innovation and research and strive to share our knowledge with the global community.
Subscribe to company announcements and press releases
Select
Select the country in which you reside:
Enter the country in which you are currently physically present:
The information contained in this section of the website of Novo Nordisk A/S (the "Company") is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "United States"), Australia, Canada, or Japan, or any jurisdiction where to do so might constitute a violation of the securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any ordinary shares or other securities of the Company in the United States, Australia, Canada, Japan, or any other jurisdiction in which such release, publication or distribution would be unlawful or would require registration or other measures.
The shares of the Company referred to in this section of the website (the "Shares") have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or in certain transactions exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. Furthermore, the Shares have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan, or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered or sold or for the account or benefit of any person having a registered address in, or located or resident in, Australia, Canada, Japan or any other jurisdiction in which it would be unlawful or would require registration or other measures.
Access to the information and documents contained on the following section of the Company's website may be illegal in certain jurisdictions, and only certain categories of persons may be authorised to access such information and documents. All persons residing outside of Denmark who wish to have access to the documents contained in this section of the Company's website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained outside Denmark. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
The use of this section of the website is subject to Danish law and any disputes arising out of or regarding this section of the website is subject to Danish law and the exclusive jurisdictions of the Danish courts.
I therefore certify that: 1.I am resident and physically present in a country outside the United States, Australia, Canada, and Japan; and 2.I am authorised to access the information and documents on this section of the website without being subject to any legal restrictions and without any further action required by the Company.
I have read, understand and agree to comply with all of the restrictions set forth above.
THE ACCESS TO THE INFORMATION AND DOCUMENTS CONTAINED IN THIS SECTION OF THE WEBSITE OF NOVO NORDISK A/S (THE "COMPANY") IS LIMITED TO PERSONS RESIDENT AND PHYSICALLY PRESENT IN DENMARK AND TO AUTHORISED PERSONS WHO ARE RESIDENT AND PHYSICALLY PRESENT IN CERTAIN OTHER JURISDICTIONS. THE INFORMATION IS MADE AVAILABLE IN CONNECTION WITH THE INITIAL PUBLIC OFFERING OF SHARES IN THE COMPANY WHICH COMPRISES (I) A PUBLIC OFFERING TO RETAIL AND INSTITUTIONAL INVESTORS IN DENMARK, (II) A PRIVATE PLACEMENT IN THE UNITED STATES ONLY TO PERSONS WHO ARE "QUALIFIED INSTITUTIONAL BUYERS" OR "QIBS" (AS DEFINED IN RULE 144A UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")) IN RELIANCE ON RULE 144A, AND (III) PRIVATE PLACEMENTS TO INSTITUTIONAL INVESTORS IN CERTAIN OTHER JURISDICTIONS. THE OFFERING OUTSIDE THE UNITED STATES WILL BE MADE IN COMPLIANCE WITH REGULATION S UNDER THE SECURITIES ACT. THE INFORMATION AND DOCUMENTS MUST NOT BE ACCESSED, COPIED OR DOWNLOADED, IN WHOLE OR IN PART, BY PERSONS PRESENT OR RESIDENT IN ANY JURISDICTION WHERE AN OFFER TO SELL OR A SOLICITATION OF ANY OFFER TO BUY ANY SECURITIES ISSUED BY THE COMPANY WOULD BE UNLAWFUL AND THE INFORMATION AND DOCUMENTS CONTAINED HEREIN ARE NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO SUCH JURISDICTIONS.
All persons residing outside of Denmark who wish to have access to the information and the documents contained in this section of the Company's website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained outside Denmark. The Company assumes no responsibility if there is a violation of applicable law or regulations by any person. In any member state of the European Economic Area ("EEA member state"), other than Denmark, that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member state, the "Prospectus Directive"), the information and the documents contained in this section of the Company's website are only addressed to and is only directed at investors in that EEA Member State who fulfil the criteria for exemption from the obligation to publish an offering circular, including qualified investors within the meaning of the Prospectus Directive as implemented in each such EEA Member State.
Any securities referred to in this section of the Company's website have not been and will not be registered under the Securities Act, and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. Any securities sold in the United States will be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) pursuant to Rule 144A.
In the United Kingdom, the information and the documents contained in this section of the Company's website are only being distributed to, and are only directed at, and any investment or investment activity to which this section of the Company's website relates is available only to, and will be engaged in only with, "qualified investors" (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). Persons who are not relevant persons should not take any action on the basis of the information and the documents contained in this section of the Company's website and should not act or rely on them.
THE CONTENTS OF THIS SECTION OF THE WEBSITE ARE NOT TO BE INCORPORATED INTO, OR CONSTRUED TO FORM PART OF, ANY OF THE DOCUMENTS INCLUDED HEREIN. EXCEPT AS OTHERWISE EXPLICITLY STATED HEREIN AS APPLICABLE TO THEM, NO INFORMATION INCLUDED ON THIS SECTION OF THE WEBSITE SHOULD BE USED BY INVESTORS IN FORMING THEIR INVESTMENT DECISION AS TO ANY SECURITIES.
The information contained in this section of the website of Novo Nordisk A/S (the "Company") is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part in, into or from the United States of America (including its territories and possessions), any state of the United States and the District of Columbia (the "United States"), Australia, Canada, Japan, or any other jurisdiction in which such release, publication or distribution would be unlawful or would require registration or other measures.
